Advertisement

Dexmedetomidine Promotes SH-SY5Y Cell Resistance Against Impairment of Iron Overload by Inhibiting NF-κB Pathways

  • Xi-bei Hu
  • Zhi-yu Xi
  • Lin-qing Liu
  • Kai Kang
  • Wan-hong Li
  • Yu-xian Shen
  • Fang Kang
  • Juan LiEmail author
Original Paper
  • 27 Downloads

Abstract

Iron overload is a common pathophysiological state underlying many diseases that has a detrimental influence on cells. The protective effects of Dexmedetomidine (Dex), a high selective alpha-2-adrenoceptor agonist, have been revealed through many experimental models, whereas no study reports its effects on an iron overload model. To elucidate these effects, we used FeCl2 with or without Dex to treat SH-SY5Y cells for 24 h and then detected indicators of oxidative stress, inflammation and apoptosis and investigated possible mechanisms further. After treatment with FeCl2 for 24 h, cell viability decreased in a dose dependent manner, and Dex promoted cell survival in FeCl2 incubation, also in a dose-dependent manner. Compared with the FeCl2 group, 20 µM Dex significantly attenuated ROS accumulation, reduced pro-inflammatory cytokine expression, and inhibited apoptosis. Furthermore, 20 µM concentration of Dex remarkably downregulated the expression of pro-apoptotic protein and activation of caspase 3 while increasing anti-apoptotic protein expression. Additionally, Dex also effectively suppressed the expression of NF-κB and its activation. In conclusion, Dex exerted anti-oxidative stress, anti-inflammation, and anti-apoptosis effects on FeCl2-treated SH-SY5Y cells, possibly by inhibiting NF-κB signaling pathway.

Keywords

Iron overload Dexmedetomidine Oxidative stress Inflammation Apoptosis NF-κB 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Tarifeno-Saldivia E, Aguilar A, Contreras D, Mercado L, Morales-Lange B, Marquez K, Henriquez A, Riquelme-Vidal C, Boltana S (2018) Iron overload is associated with oxidative stress and nutritional immunity during viral infection in fish. Front Immunol 9:1296CrossRefGoogle Scholar
  2. 2.
    Frey PA, Reed GH (2012) The ubiquity of iron. ACS Chem Biol 7:1477–1481CrossRefGoogle Scholar
  3. 3.
    Lee DG, Kam MK, Kim KM, Kim HS, Kwon OS, Lee HS, Lee DS (2018) Peroxiredoxin 5 prevents iron overload-induced neuronal death by inhibiting mitochondrial fragmentation and endoplasmic reticulum stress in mouse hippocampal HT-22 cells. Int J Biochem Cell Biol 102:10–19CrossRefGoogle Scholar
  4. 4.
    Garton T, Keep RF, Hua Y, Xi G (2016) Brain iron overload following intracranial haemorrhage. Stroke Vasc Neurol 1:172–184CrossRefGoogle Scholar
  5. 5.
    Zhang L, Hu R, Li M, Li F, Meng H, Zhu G, Lin J, Feng H (2013) Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci 34:639–645CrossRefGoogle Scholar
  6. 6.
    Apostolakis S, Kypraiou AM (2017) Iron in neurodegenerative disorders: being in the wrong place at the wrong time? Rev Neurosci 28:893–911CrossRefGoogle Scholar
  7. 7.
    Crichton RR, Wilmet S, Legssyer R, Ward RJ (2002) Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 91:9–18CrossRefGoogle Scholar
  8. 8.
    Civantos Calzada B, Aleixandre de Artinano A (2001) Alpha-adrenoceptor subtypes. Pharmacol Res 44:195–208CrossRefGoogle Scholar
  9. 9.
    Pertovaara A (2013) The noradrenergic pain regulation system: a potential target for pain therapy. Eur J Pharmacol 716:2–7CrossRefGoogle Scholar
  10. 10.
    Zarbock A, Milles K (2015) Novel therapy for renal protection. Curr Opin Anaesthesiol 28:431–438CrossRefGoogle Scholar
  11. 11.
    Weerink MA, Struys MM, Hannivoort LN, Barends CR, Absalom AR, Colin P (2017) Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet 56(8):893–913CrossRefGoogle Scholar
  12. 12.
    Yoon JY, Park JH, Kim EJ, Park BS, Yoon JU, Shin SW, Kim DW (2016) Dexmedetomidine attenuates H2O2-induced cell death in human osteoblasts. J Dental Anesth Pain Med 16:295–302CrossRefGoogle Scholar
  13. 13.
    Zhang W, Zhang J (2017) Dexmedetomidine preconditioning protects against lung injury induced by ischemia-reperfusion through inhibition of autophagy. Exp Ther Med 14:973–980CrossRefGoogle Scholar
  14. 14.
    Akpinar O, Naziroglu M, Akpinar H (2017) Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats. Brain Res Bull 130:1–9CrossRefGoogle Scholar
  15. 15.
    Liu Y, Li J, Xu K, Gu J, Huang L, Zhang L, Liu N, Kong J, Xing M, Zhang L, Zhang L (2018) Characterization of superparamagnetic iron oxide nanoparticle-induced apoptosis in PC12 cells and mouse hippocampus and striatum. Toxicol Lett 292:151–161CrossRefGoogle Scholar
  16. 16.
    Wang BF, Cui ZW, Zhong ZH, Sun YH, Sun QF, Yang GY, Bian LG (2015) Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression. Acta Pharmacol Sin 36:939–948CrossRefGoogle Scholar
  17. 17.
    Lee DG, Park J, Lee HS, Lee SR, Lee DS (2016) Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells. Toxicology 365:17–24CrossRefGoogle Scholar
  18. 18.
    Cui ZW, Xie ZX, Wang BF, Zhong ZH, Chen XY, Sun YH, Sun QF, Yang GY, Bian LG (2015) Carvacrol protects neuroblastoma SH-SY5Y cells against Fe(2+)-induced apoptosis by suppressing activation of MAPK/JNK-NF-kappaB signaling pathway. Acta Pharmacol Sin 36:1426–1436CrossRefGoogle Scholar
  19. 19.
    Bautista E, Vergara P, Segovia J (2016) Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells. J Trace Elem Med Biol 34:62–69CrossRefGoogle Scholar
  20. 20.
    Wu GJ, Chen JT, Tsai HC, Chen TL, Liu SH, Chen RM (2017) Protection of dexmedetomidine against ischemia/reperfusion-induced apoptotic insults to neuronal cells occurs via an intrinsic mitochondria-dependent pathway. J Cell Biochem 118:2635–2644CrossRefGoogle Scholar
  21. 21.
    Chi OZ, Grayson J, Barsoum S, Liu X, Dinani A, Weiss HR (2015) Effects of dexmedetomidine on microregional O2 balance during reperfusion after focal cerebral ischemia. J Stroke Cerebrovasc Dis 24:163–170CrossRefGoogle Scholar
  22. 22.
    Liu W, Yu W, Weng Y, Wang Y, Sheng M (2017) Dexmedetomidine ameliorates the inflammatory immune response in rats with acute kidney damage. Exp Ther Med 14:3602–3608CrossRefGoogle Scholar
  23. 23.
    Hu H, Shi D, Hu C, Yuan X, Zhang J, Sun H (2017) Dexmedetomidine mitigates CLP-stimulated acute lung injury via restraining the RAGE pathway. Am J Transl Res 9:5245–5258Google Scholar
  24. 24.
    Liu XR, Li T, Cao L, Yu YY, Chen LL, Fan XH, Yang BB, Tan XQ (2018) Dexmedetomidine attenuates H2O2-induced neonatal rat cardiomyocytes apoptosis through mitochondria- and ER-medicated oxidative stress pathways. Mol Med Rep 17:7258–7264Google Scholar
  25. 25.
    Breuer T, Bleilevens C, Rossaint R, Marx G, Gehrenkemper J, Dierksen H, Delpierre A, Weis J, Gayan-Ramirez G, Bruells CS (2018) Dexmedetomidine impairs diaphragm function and increases oxidative stress but does not aggravate diaphragmatic atrophy in mechanically ventilated rats. Anesthesiology 128:784–795CrossRefGoogle Scholar
  26. 26.
    Heil LB, Santos CL, Santos RS, Samary CS, Cavalcanti VC, Araujo MM, Poggio H, Maia LA, Trevenzoli IH, Pelosi P, Fernandes FC, Villela NR, Silva PL, Roccoet PR (2016) The effects of short-term propofol and dexmedetomidine on lung mechanics, histology, and biological markers in experimental obesity. Anesth Analg 122:1015–1023CrossRefGoogle Scholar
  27. 27.
    Ueki M, Kawasaki T, Habe K, Hamada K, Kawasaki C, Sata T (2014) The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia 69:693–700CrossRefGoogle Scholar
  28. 28.
    Wang K, Li C (2018) Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-kappaB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma. Oncol Lett 15:7153–7157Google Scholar
  29. 29.
    Luo C, Ouyang MW, Fang YY, Li SJ, Zhou Q, Fan J, Qin ZS, Tao T (2017) Dexmedetomidine protects mouse brain from ischemia-reperfusion injury via inhibiting neuronal autophagy through up-regulating HIF-1alpha. Front Cell Neurosci 11:197CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Xi-bei Hu
    • 1
    • 2
  • Zhi-yu Xi
    • 3
  • Lin-qing Liu
    • 4
  • Kai Kang
    • 5
  • Wan-hong Li
    • 2
  • Yu-xian Shen
    • 6
  • Fang Kang
    • 2
  • Juan Li
    • 1
    • 2
    • 7
    Email author
  1. 1.School of MedicineShandong UniversityJinanChina
  2. 2.Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Science and MedicineUniversity of Science and Technology of ChinaHefeiChina
  3. 3.Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong UniversitySchool of MedicineShanghaiChina
  4. 4.Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Science and MedicineUniversity of Science and Technology of ChinaHefeiChina
  5. 5.Department of AnesthesiologyZhejiang HospitalHangzhouChina
  6. 6.School of Basic Medical SciencesAnhui Medical UniversityHefeiChina
  7. 7.Department of AnesthesiologyThe First Affiliated Hospital of USTC (South District)HefeiChina

Personalised recommendations